Video
Sam Costello (The Queen Elizabeth Hospital in Adelaide) presented recent evidences about FMT and IBDs.
Ghaith Bakdash described how Microbiotica discovered a specific microbiome signature in patients responder to immune-oncology drugs such as anti-PD1 / PDL1 and developed a new bacterial consortium.
Sarah Lebeer (Research professor, University of Antwerp) described how she and her colleagues developed a new probiotic topic formulation to treat Acne.
Holger Lenz discusses the interest of Bayer in the microbiome space during Microbiome Connect: Europe 2022.
Maria Teresa Abreu (University of Miami, USA) discussed some new strategies to design clinical trials.
Theresa Pizarro, (Case Western Reserve University School of Medicine) discussed the roles of epithelial barrier’s cytokines, gut microbiome and Gasdermin in IBD patients.
Sudarshen Paramsothy (University of New South Wales, Australia) discussed the controversials about FMT in IBD patients.
Herbert Tilg (University Innsbruck, Austria) discussed the relationship between Inflammatory Bowel Diseases and gut microbiome.
Niall Hyland (University College Cork) discussed the research on gut brain axis and the potential role of psychobiotics.
Simone Guglielmetti (University of Milan) discusses the use of inactivated microbes as alternative to live probiotics.
